251 related articles for article (PubMed ID: 15306832)
21. [Treatment of diabetes in metabolic syndrome].
Pelikánova T
Vnitr Lek; 2009; 55(7-8):637-45. PubMed ID: 19731868
[TBL] [Abstract][Full Text] [Related]
22. Glycemic Control and Excess Cardiovascular Mortality in Type 1 Diabetes.
Teleb M; Popp Switzer M; Elhanafi S; Elfar A; San Juan ZT
Curr Cardiol Rep; 2016 Mar; 18(3):29. PubMed ID: 26886228
[TBL] [Abstract][Full Text] [Related]
23. Before oral agents fail: the case for starting insulin early.
Marre M
Int J Obes Relat Metab Disord; 2002 Sep; 26 Suppl 3():S25-30. PubMed ID: 12174320
[TBL] [Abstract][Full Text] [Related]
24. Influence of intensive versus conventional glucose control on microvascular and macrovascular complications in type 1 and 2 diabetes mellitus.
Mattila TK; de Boer A
Drugs; 2010 Dec; 70(17):2229-45. PubMed ID: 21080740
[TBL] [Abstract][Full Text] [Related]
25. Macrovascular and microvascular outcomes after beginning of insulin versus additional oral glucose-lowering therapy in people with type 2 diabetes: an observational study.
Hall GC; McMahon AD; Carroll D; Home PD
Pharmacoepidemiol Drug Saf; 2012 Mar; 21(3):305-13. PubMed ID: 22271442
[TBL] [Abstract][Full Text] [Related]
26. [Clinical study of the month. After DCCT, the EDIC study].
Scheen AJ
Rev Med Liege; 2000 Mar; 55(3):187-9. PubMed ID: 10823011
[TBL] [Abstract][Full Text] [Related]
27. Reduction of cardiovascular morbidity and mortality in type 2 diabetes. A rational approach to hypoglycemic therapy.
Spallarossa P; Barsotti A; Cordera R; Ghigliotti G; Maggi D; Brunelli C
J Endocrinol Invest; 2004 May; 27(5):485-95. PubMed ID: 15279085
[TBL] [Abstract][Full Text] [Related]
28. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial.
White NH; Sun W; Cleary PA; Danis RP; Davis MD; Hainsworth DP; Hubbard LD; Lachin JM; Nathan DM
Arch Ophthalmol; 2008 Dec; 126(12):1707-15. PubMed ID: 19064853
[TBL] [Abstract][Full Text] [Related]
29. Insights from the diabetes control and complications trial/epidemiology of diabetes interventions and complications study on the use of intensive glycemic treatment to reduce the risk of complications of type 1 diabetes.
Genuth S
Endocr Pract; 2006; 12 Suppl 1():34-41. PubMed ID: 16627378
[TBL] [Abstract][Full Text] [Related]
30. Beneficial and detrimental effects of intensive glycaemic control, with emphasis on type 2 diabetes mellitus.
Camacho P; Pitale S; Abraira C
Drugs Aging; 2000 Dec; 17(6):463-76. PubMed ID: 11200307
[TBL] [Abstract][Full Text] [Related]
31. The pathophysiological basis for intensive insulin replacement.
Rolla A
Int J Obes Relat Metab Disord; 2004 Sep; 28 Suppl 2():S3-7. PubMed ID: 15306831
[TBL] [Abstract][Full Text] [Related]
32. First approved inhaled insulin therapy for diabetes mellitus.
Jani R; Triplitt C; Reasner C; Defronzo RA
Expert Opin Drug Deliv; 2007 Jan; 4(1):63-76. PubMed ID: 17184163
[TBL] [Abstract][Full Text] [Related]
33. Postprandial hyperglycemia and endothelial function in type 2 diabetes: focus on mitiglinide.
Kitasato L; Tojo T; Hatakeyama Y; Kameda R; Hashikata T; Yamaoka-Tojo M
Cardiovasc Diabetol; 2012 Jun; 11():79. PubMed ID: 22748110
[TBL] [Abstract][Full Text] [Related]
34. New insulins and newer insulin regimens: a review of their role in improving glycaemic control in patients with diabetes.
Gururaj Setty S; Crasto W; Jarvis J; Khunti K; Davies MJ
Postgrad Med J; 2016 Mar; 92(1085):152-64. PubMed ID: 26842973
[TBL] [Abstract][Full Text] [Related]
35. Cardiovascular benefits of exogenous insulin.
Chaudhuri A; Dandona P; Fonseca V
J Clin Endocrinol Metab; 2012 Sep; 97(9):3079-91. PubMed ID: 22723317
[TBL] [Abstract][Full Text] [Related]
36. [Good glycaemic control can prevent diabetic peripheral neuropathy].
Gregersen S
Ugeskr Laeger; 2013 Sep; 175(36):2022-5. PubMed ID: 23992909
[TBL] [Abstract][Full Text] [Related]
37. Effect of inhaled insulin on fasting and postprandial plasma glucose.
Mikhail NE; Wali S; Cope D
Ann Intern Med; 2007 Jun; 146(11):821; author reply 821-2. PubMed ID: 17548418
[No Abstract] [Full Text] [Related]
38. Type 2 diabetes among women: clinical considerations for pharmacological management to achieve glycemic control and reduce cardiovascular risk.
Levine JP
J Womens Health (Larchmt); 2008 Mar; 17(2):249-60. PubMed ID: 18321176
[TBL] [Abstract][Full Text] [Related]
39. Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) Study.
Albers JW; Herman WH; Pop-Busui R; Feldman EL; Martin CL; Cleary PA; Waberski BH; Lachin JM;
Diabetes Care; 2010 May; 33(5):1090-6. PubMed ID: 20150297
[TBL] [Abstract][Full Text] [Related]
40. [Metabolic control or reduction of vascular risk with current treatments. What is the priority?].
Alonso Fernández M
Semergen; 2018 Jun; 44 Suppl 1():26-32. PubMed ID: 30322470
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
